A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.

Gynecologic Oncology
Halla S NimeiriG F Fleming

Abstract

To determine the efficacy and safety of single agent sorafenib, an oral multi-targeted tyrosine kinase inhibitor, in patients with advanced uterine carcinoma and carcinosarcoma. This multi-institutional non-randomized phase II trial enrolled two cohorts: patients with uterine carcinoma (cohort A) and uterine carcinosarcoma (cohort B). Eligibility criteria included measurable disease, 0-1 prior chemotherapy regimens, and ECOG performance status <or=2. Sorafenib at a dose of 400 mg was administered orally twice daily. A cycle was defined as 28 days. Objective tumor response was the primary endpoint and was assessed following every two cycles. Fifty-six patients (40 with carcinoma, 16 with carcinosarcoma) were enrolled between March 2005 and August 2007. Two (5%) patients with uterine carcinoma had a partial response (PR) and 17 (42.5%) achieved stable disease (SD). Five had SD lasting at least 4 months. The 6-month progression-free survival rate for patients with carcinoma was 29%, and the median overall survival was 11.4 months. No patients with carcinosarcoma had an objective response. Four (25%) had SD, and one had SD lasting 18 months. The 6-month progression-free survival rate was 13%, and the median overall survival was 5.0...Continue Reading

References

Nov 26, 2002·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·W G McCluggage
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gini F FlemingR Tucker Burks
Oct 2, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Tate ThigpenShu Liao
Sep 26, 2006·Gynecologic Oncology·A R GünthertUNKNOWN Arbeitsgemeinschaft Gynaekologische Onkologie
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Feb 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard D HomesleyUNKNOWN Gynecologic Oncology Group
Dec 21, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Aparna A KamatAnil K Sood
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alvaro Moreno-AspitiaEdith A Perez
Dec 5, 2008·The New England Journal of Medicine·Giancarlo Spinzi, Silvia Paggi
Apr 15, 2009·Anti-cancer Drugs·Paulo Cortes
Jul 29, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pingfu FuMark Schluchter

❮ Previous
Next ❯

Citations

Mar 13, 2013·Women's Health·Duangmani ThanapprapasrDavid G Mutch
Jan 5, 2011·Frontiers in Bioscience (Scholar Edition)·Amy R CarrollAnil K Sood
Feb 22, 2012·Expert Opinion on Investigational Drugs·Marco PetrilloGabriella Ferrandina
Jun 21, 2013·Expert Opinion on Investigational Drugs·Xia-wei WeiYu-Quan Wei
Sep 11, 2010·Expert Opinion on Emerging Drugs·Ozden AltundagAli Ayhan
Apr 24, 2012·Hematology/oncology Clinics of North America·Behrouz ZandAnil K Sood
Jan 17, 2012·Hematology/oncology Clinics of North America·Neil Horowitz, Ursula A Matulonis
Sep 14, 2010·Critical Reviews in Oncology/hematology·Giannis MountziosChristos A Papadimitriou
Oct 19, 2011·Obstetrics and Gynecology International·Rani Kanthan, Jenna-Lynn Senger
Feb 29, 2016·Current Oncology Reports·Victor Rodriguez-FreixinosAmit M Oza
Sep 17, 2015·Current Treatment Options in Oncology·Joseph Menczer
Mar 14, 2014·The Journal of Clinical Hypertension·Yan LiBenkang Shi
Dec 11, 2013·The Journal of Obstetrics and Gynaecology Research·Tomomaro Etoh, Hidekatsu Nakai
Oct 5, 2015·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Muhieddine SeoudKeiichi Fujiwara
Jul 2, 2015·Critical Reviews in Oncology/hematology·Angiolo GadducciClaudia Sergiampietri
Mar 26, 2015·Gynecologic Oncology·Leigh A CantrellLinda R Duska
Mar 13, 2014·Critical Reviews in Oncology/hematology·Yvonne M H Versleijen-JonkersWinette T A van der Graaf
Dec 21, 2010·Gynecologic Oncology·Whitfield B GrowdonDarrell R Borger
Dec 4, 2014·Critical Reviews in Oncology/hematology·Grazia ArtioliFranco Garbin
Mar 10, 2015·Current Treatment Options in Oncology·Bernd C Schmid, Martin K Oehler
Jun 12, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Cristina MirantesXavier Dolcet
May 10, 2013·The New England Journal of Medicine·Richard T PensonEsther Oliva
Jan 6, 2017·Autophagy·Núria EritjaDavid Llobet-Navàs
Apr 9, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vinay PrasadTito Fojo
Jul 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gini F Fleming
Dec 8, 2017·Gynecologic Oncology Research and Practice·Vicky MakkerDavid Scott Miller
Jul 5, 2018·Expert Review of Anticancer Therapy·Elizabeth V Connor, Peter G Rose
Feb 12, 2017·F1000Research·Arthur-Quan Tran, Paola Gehrig
Jul 2, 2010·British Journal of Pharmacology·Gabriela B IwanskiH Phillip Koeffler
Jul 15, 2016·The Oncologist·Christine M Bestvina, Gini F Fleming
Jun 16, 2011·Current Opinion in Oncology·Daliah Tsoref, Amit M Oza
Dec 22, 2011·Obstetrical & Gynecological Survey·Mahalakshmi GurumurthyDavid E Parkin
Mar 29, 2012·The Kaohsiung Journal of Medical Sciences·Chia-Lun WuDah-Shyong Yu
Dec 21, 2010·Expert Review of Anticancer Therapy·Cathrine Holland
Mar 22, 2014·Molecular and Clinical Oncology·Yuya NogamiDaisuke Aoki
Jul 28, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Duangmani Thanapprapasr, Kamolrat Thanapprapasr
Sep 21, 2018·American Society of Clinical Oncology Educational Book·Ilaria ColomboAmit M Oza
Jun 15, 2013·American Journal of Clinical Oncology·Leslie S BradfordDon S Dizon
Sep 1, 2015·American Journal of Therapeutics·XiongWen YangYingZhang Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Carcinosarcoma

Carcinosarcoma is a malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. Discover the latest research on carcinosarcoma here.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.